While albumin-based nanoparticles have demonstrated clinical success in cancer therapy—most notably with nab-paclitaxel (Abraxane®) [34,35]—and curcumin-loaded nanocarriers have shown promise in preclinical glioblastoma models [36,37], the present study introduces a novel therapeutic approach that addresses critical gaps in existing strategies. Here, ALB is linked to glioblastoma.